PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media278701ArticlesСтатьиSYSTEMIC ATHEROSCLEROSIS IN THERAPEUTIC PRACTICE: TOWARDS THE OPTIMIZATION OF MANAGEMENTРАСПРОСТРАНЕННЫЙ АТЕРОСКЛЕРОЗ В ОБЩЕТЕРАПЕВТИЧЕСКОЙ ПРАКТИКЕ: НА ПУТИ К ОПТИМИЗАЦИИ ТАКТИКИ ВЕДЕНИЯFominV VFominViktor ViktorovichФоминВиктор Викторович

ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России, Москва

ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России, Москва200920101718-19NO18-19 (2010)№18-19 (2010)273123022023Copyright ©; 2010, Bionika MediaCopyright ©; 2010, ООО «Бионика Медиа»2010Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/278701

The article discusses modern approaches to early detection of preclinical markers of systemic atherosclerosis and management of these patients. It is emphasized that the currently available instrumental methods of early preclinical diagnosis of atherosclerosis of major vascular territories are particularly important in terms of timely optimizing of therapeutic strategy. Maximum use of treatment modalities includes administration of ACE inhibitors and pentoxifylline in these patients

Обсуждаются современные подходы к раннему выявлению доклинических маркеров распространенного атеросклероза и ведению этой категории больных. Подчеркивается, что доступные сегодня инструментальные методы ранней доклинической диагностики атеросклеротического поражения основных сосудистых бассейнов приобретают особое значение с точки зрения своевременной оптимизации терапевтической стратегии. Максимальное использование возможностей лечения подразумевает в т. ч. применение у этих больных ингибиторов АПФ и пентоксифиллина.

atherosclerosiscarotid arteriesintermittent clauscidationpentoxiphyllineACE inhibitorsатеросклерозсонные артериисиндром перемежающейся хромотыпентоксифиллинингибиторы АПФДиагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов // Системные гипертензии. 2010. № 3. С. 5-26.Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998;128:262-69.Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:1432-37.Burke G, Evans G, Riley W, et al. Arterial wall thickness is associated with prvalent cardiovascular diseases in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995;26:386-91.Li R, Duncan BB, Metcalf PA, et al. B-mode-detected carotid artery plaque in a general population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke. 1994;25:2377-83.Duncan BB, Metcalf P, Crouse JR, et al. Risk factors differ for carotid artery plaque with and without acoustic shadowing. Atherosclerosis Risk in Communities Study Investigators. J Neuroimaging 1997;7:28-34.Stevens J, Tyroler HA, Cai J, et al. Body weight change and carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1998;147:563-73.Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000;151:478-87.O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14-22.Ogata T, Yasaka M, Yamagishi M, et al. Atherosclerosis found on carotid ultrasonography is associated with atherosclerosis on coronary intravascular ultrasonography. J Ultrasound Med 2005;24:469-74.Shammas NW. Epidemiology, classification and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag 2007;3(2):229-94.Weitz JI, Byrne J, Clagett P, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996;94:3026-49.Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-86.Dieter RS, Tomasson J, Gudjonsson T, et al. Lower extremity peripheral arterial disease in hospitalized patients with coronary artery disease. Vasc Med 2003;8(4):233-36.Criqui MH, Ninomiya JK, Wingard D, et al. Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. J Am Coll Cardiol 2008;52(21):1736-42.Moussa ID, Jaff MR, Mehran R, et al. Prevalence and prediction of previously unrecognized peripheral arterial disease in patients with coronary artery disease: the Peripheral Arterial Disease in Interventional Patients Study. Catheter Cardiovasc Interv 2009;73(6):719-24.Sigvant B, Wiberg-Hedman K, Bergqvist D, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg 2007;45(6):1185-91.Kownator S, Cambou JP, Cacoub P, et al. Prevalence of unknown peripheral arterial disease in patients with coronary artery disease: data in primary care from the IPSILON study. Arch Cardiovasc Dis 2009;102(8-9):625-31.Mourad JJ, Cacoub P, Collet JP, et al.; ELLIPSE scientific committee and study investigators. Screening of unrecognized peripheral arterial disease (PAD) using ankle brachial index in high cardiovascular risk patients free from symptomatic PAD. J Vasc Surg 2009;50(3):572-80.Jaar BG, Plantinga LC, Astor BC, et al. Novel and traditional cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients. Adv Chronic Kidney Dis 2007;14(3):304-13.Fukuhara M, Geary RL, Diz DI, et al. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 2000;35(1 Pt. 2):353-59.Sluimer JC, Gasc JM, Hamming I, et al. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J Pathol 2008;215(3):273-79.Ohishi M, Ueda M, Rakugi H, et al. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens 1997;15(11):1295-302.Lonn E, Yusuf S, Dzavik V, et al.; SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001;103(7):919-25.Lane DA, Lip GY. Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev 2009;(4):CD003075.Kokesh J, Kazmers A, Zierler RE. Pentoxifylline in the nonoperative management of intermittent claudication. Ann Vasc Surg 1991;5(1):66-70.Mangiafico RA, Fiore CE. Current management of intermittent claudication: the role of pharmacological and nonpharmacological symptom-directed therapies. Curr Vasc Pharmacol 2009;7(3):394-413.Prasad K, Lee P. Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis 2007;192(2):313-22.Chen YM, Wu KD, Tsai TJ, et al. Pentoxifylline inhibits PDGF-induced proliferation of and TGF-beta-stimulated collagen synthesis by vascular smooth muscle cells. J Mol Cell Cardiol 1999;31(4):773-83.Maiti R, Agrawal NK, Dash D, et al. Effect of Pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients. Vascul Pharmacol 2007;47(2-3):118-24.Fernandes JL, de Oliveira RT, Mamoni R. Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease-a randomized placebo controlled study. Atherosclerosis 2008;196(1):434-42.Жданова И.В., Цвиренко С.В., Барац С.С. и др. Влияния флувастатина и его комбинации с аспирином и тренталом на гемостаз и микроциркуляцию при атеросклерозе // Терапевтический архив. 2002. № 74(8). С. 9-12.